The International Diabetes Federation has recently published a position statement on bariatric surgery. Facing a global diabetes crisis, it has added various types of surgery on the gastrointestinal tract as powerful options among the armamentarium to normalise glycaemia, avoid regular medications and decrease costs in severely obese patients. Laparoscopic sleeve gastrectomy has been shown to be effective for the treatment of type 2 diabetes, with extremely low mortality and acceptable morbidity. It decreases caloric consumption, modifies gut hormones, changes gastric emptying, and lowers glycaemia. In the long term, if recurrences in weight or diabetes occur, it can be converted to a duodenal switch, potentially reaching 90% of patients with partial or complete remission.
Laparoscopic sleeve gastrectomy was initially described as a stage procedure for high-risk patients, followed six months later with either a full duodenal switch or gastric bypass. 1 Laparoscopic sleeve gastrectomy is now the dominant weight-loss surgery in the US, an achievement that was never attained with the less invasive adjustable gastric banding.
American patients are choosing this procedure at a ratio of 2:1, instead of a Roux-en-Y gastric bypass, which was the gold standard for several decades. Compared with gastric bypass, the procedure causes less short-and long-term morbidity; preserves the full length of the intestine for micronutrients absorption; preserves the pylorus for gastric emptying; causes less rebound hypoglycaemia; and has similar effects and rates of comorbidity resolution and percentage of excess weight loss.
From the surgeon's perspective, the procedure is easier to perform (no intestinal anastomosis), with shorter anaesthesia and simplified follow- was 'cured' in 93% of patients, 20 years after a duodenal switch. 4 The procedure has been simplified lately with a single anastomosis duodenal switch or single anastomosis duodeno-ileostomy (SADI), with similar results after five years, but with lesser operating time, complications and diminished side effects, from a group in Madrid (Prof. Antonio Torres and Dr Andres Sanchez-Pernaute, from Hospital Clinico San Carlos). 5 These effects are not surprising when one notes that sleeve gastrectomy has a restrictive component due to its reduced volume (>80%), decreased total acid production, hormonal changes with reduced serum ghrelin production (70%), increased post-prandial glucagon-like peptide-1 and peptide YY 3-36, and is lately associated with increased circulating bile acids, changes to gut microbial flora and farsenoid-X receptor signalling. 6 Hence, I believe the future of sleeve gastrectomy is bright and it will probably become the primary procedure in >75% of patients seeking weight-loss surgery and/or type 2 diabetes surgery. ■
